BioSpace News Archive

Biofidelity Ltd, the cancer diagnostics company, announced the successful completion of alpha testing of its new ASPYRE-Lung reagents at multiple laboratory locations in the US and UK.

KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, announced that the U.S. Food and Drug Administration has lifted the clinical hold on the Company’s Phase 2 clinical trial of KVD824 for oral prophylactic treatment of hereditary angioedema.

Matinas BioPharma Holdings, Inc., announced that Jerome D. Jabbour, Chief Executive Officer, presented a Company overview at the H.C. Wainwright 23rd Annual Global Investment Conference being held virtually September 13-15, 2021.

Amgen announced that Health Canada has approved LUMAKRASTM for the treatment of adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer who have received at least one prior systemic therapy.

AlivaMab Discovery Services Announces Multi-Target Agreement with Teva Pharmaceuticals Agreement aims to accelerate the discovery of new therapeutics

PureTech Health plc today announced that George Farmer, Ph.D., Chief Financial Officer, will present at the Oppenheimer Fall Healthcare Life Sciences and MedTech Summit on September 21, 2021 at 4:35 PM EDT.

Beyond Air, Inc. today announced that Steve Lisi, Chairman and Chief Executive Officer of Beyond Air, is scheduled to present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit being held virtually from September 20th to 23rd.

Nanoscope researchers were awarded a $1.5 million Phase 2b Small Business Research Innovation (SBIR) grant by the National Eye Institute (NEI) of the National Institutes of Health (NIH) to advance the company’s ambient light activatable optogenetic gene therapy for age-related macular degeneration (AMD).

Adaptive Phage Therapeutics, Inc. today announced the appointment of Jesse L. Goodman, MD, MPH, to the company’s Board of Directors.

Luminopia today announced the publication of positive Phase 3 pivotal data of its investigational treatment for amblyopia—Luminopia One